Nectin-4

Gene

Related News

Samsung Bioepis advances first new drug SBE303 into global Phase 1 trial

Apr 14, 2026

Samsung Bioepis plans to start a global Phase 1 trial of SBE303, its first independently developed new drug candidate targeting Nectin-4. Preclinical data showed tolerability up to 40 mg/kg in monkeys.

Celltrion’s CT-P71 receives FDA Fast Track designation for urothelial cancer

Apr 09, 2026

Celltrion said CT-P71 received FDA Fast Track designation for previously treated locally advanced or metastatic urothelial cancer. The ADC candidate is in Phase 1 testing.